UA123201C2 - Спосіб отримання сполуки діарилтіогідрантоїну - Google Patents
Спосіб отримання сполуки діарилтіогідрантоїнуInfo
- Publication number
- UA123201C2 UA123201C2 UAA201707588A UAA201707588A UA123201C2 UA 123201 C2 UA123201 C2 UA 123201C2 UA A201707588 A UAA201707588 A UA A201707588A UA A201707588 A UAA201707588 A UA A201707588A UA 123201 C2 UA123201 C2 UA 123201C2
- Authority
- UA
- Ukraine
- Prior art keywords
- preparation
- diarylthiohydantoin compound
- compound
- diarylthiohydantoin
- intermediates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/14—Phosphorus; Compounds thereof
- B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
- B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
- B01J27/198—Vanadium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/04—Mixing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Пропонуються способи й проміжні сполуки для отримання сполуки (X), яку в даний час досліджують для лікування раку простати.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094436P | 2014-12-19 | 2014-12-19 | |
| PCT/US2015/066356 WO2016100652A2 (en) | 2014-12-19 | 2015-12-17 | Process for the preparation of a diarylthiohydantoin compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA123201C2 true UA123201C2 (uk) | 2021-03-03 |
Family
ID=55168400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201707588A UA123201C2 (uk) | 2014-12-19 | 2015-12-17 | Спосіб отримання сполуки діарилтіогідрантоїну |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9688655B2 (uk) |
| EP (4) | EP3372585B1 (uk) |
| JP (2) | JP6681902B2 (uk) |
| KR (1) | KR102586059B1 (uk) |
| CN (1) | CN107108507A (uk) |
| AR (1) | AR103228A1 (uk) |
| AU (1) | AU2015364537B2 (uk) |
| BR (1) | BR112017013113B1 (uk) |
| CA (1) | CA2970937A1 (uk) |
| CY (2) | CY1121684T1 (uk) |
| DK (3) | DK3372585T3 (uk) |
| EA (4) | EA201892485A1 (uk) |
| ES (3) | ES2919951T3 (uk) |
| HR (3) | HRP20220750T1 (uk) |
| HU (2) | HUE052475T2 (uk) |
| IL (1) | IL252843A0 (uk) |
| LT (3) | LT3372584T (uk) |
| MA (1) | MA41200B1 (uk) |
| MD (1) | MD3233803T2 (uk) |
| ME (1) | ME03420B (uk) |
| MX (1) | MX2017008179A (uk) |
| NZ (1) | NZ732766A (uk) |
| PH (1) | PH12017501152A1 (uk) |
| PL (3) | PL3372584T3 (uk) |
| PT (3) | PT3372584T (uk) |
| RS (3) | RS61060B9 (uk) |
| SG (4) | SG10201912811QA (uk) |
| SI (3) | SI3233803T1 (uk) |
| TR (1) | TR201904739T4 (uk) |
| TW (4) | TWI689494B (uk) |
| UA (1) | UA123201C2 (uk) |
| WO (1) | WO2016100652A2 (uk) |
| ZA (1) | ZA201704877B (uk) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016100652A2 (en) * | 2014-12-19 | 2016-06-23 | Aragon Pharmaceuticals, Inc. | Process for the preparation of a diarylthiohydantoin compound |
| HUE042349T2 (hu) | 2014-12-19 | 2019-06-28 | Aragon Pharmaceuticals Inc | Eljárás diariltiohidantoin vegyület elõállítására |
| CN108069869B (zh) * | 2016-11-09 | 2022-03-01 | 上海医药工业研究院 | 一种Apalutamide的制备方法及其中间体 |
| TW201831461A (zh) * | 2017-01-18 | 2018-09-01 | 台灣神隆股份有限公司 | 製備阿帕魯醯胺的方法 |
| US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| CN107501237B (zh) * | 2017-08-17 | 2022-03-22 | 上海西浦医药科技有限公司 | 一种Apalutamide的合成方法 |
| CN108383749B (zh) * | 2018-01-30 | 2021-03-09 | 杭州科巢生物科技有限公司 | 阿帕鲁胺的合成方法及其中间体 |
| US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
| CN108314646B (zh) * | 2018-04-11 | 2021-03-19 | 武汉慧敏科技中心 | 一种高分散双金属纳米材料制备泌尿生殖***用药物中间体的方法 |
| CN109651256A (zh) * | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式（viii）的恩杂鲁胺的制备方法 |
| CN110511207A (zh) * | 2019-06-17 | 2019-11-29 | 扬子江药业集团江苏海慈生物药业有限公司 | 芳基-2-硫代海因类化合物中间体、其制备方法及应用 |
| CN110511206A (zh) * | 2019-06-17 | 2019-11-29 | 扬子江药业集团江苏海慈生物药业有限公司 | 芳基-2-硫代海因类化合物中间体、其制备方法及应用 |
| WO2022049265A1 (en) | 2020-09-04 | 2022-03-10 | Synthon B.V. | Improved process for preparation of apalutamide |
| CN113292535B (zh) * | 2021-06-18 | 2022-07-01 | 南京方生和医药科技有限公司 | 一种制备阿帕鲁胺中间体及阿帕鲁胺的方法 |
| CN113402466B (zh) * | 2021-06-18 | 2022-08-16 | 南京方生和医药科技有限公司 | 一种阿帕鲁胺中间体及制备阿帕鲁胺的方法 |
| CN115850233A (zh) * | 2021-09-24 | 2023-03-28 | 南京方生和医药科技有限公司 | 一种阿帕鲁胺的合成方法 |
| CN115536634A (zh) * | 2022-10-17 | 2022-12-30 | 上海博悦生物科技有限公司 | 一种阿帕他胺的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077605A1 (en) | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| EP3412290B1 (en) | 2006-03-27 | 2021-03-03 | The Regents of The University of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| US8461343B2 (en) * | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| BRPI0912802A2 (pt) * | 2008-05-16 | 2015-10-13 | Takeda San Diego Inc | ativadores de glicoquinase |
| EA019970B8 (ru) * | 2009-12-11 | 2014-11-28 | Отифони Терапеутикс Лимитед | Производные имидазолидиндиона |
| SI3124481T1 (en) * | 2010-02-16 | 2018-06-29 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and their use |
| BR112012021406B1 (pt) * | 2010-02-24 | 2021-08-10 | Medivation Prostate Therapeutics Llc | Processos para a síntese dos compostos de diariltioidantoína e diarilidantoína |
| CN103608333B (zh) * | 2011-03-10 | 2016-01-06 | 苏州开拓药业有限公司 | 雄激素受体拮抗剂及其用途 |
| WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| CN104379160A (zh) * | 2012-03-29 | 2015-02-25 | 桑加特公司 | 双阿司匹林交联聚乙二醇化血红蛋白 |
| US9708289B2 (en) * | 2013-05-29 | 2017-07-18 | Hinova Pharmaceuticals Inc. | Imidazole diketone compound and use thereof |
| WO2016100652A2 (en) * | 2014-12-19 | 2016-06-23 | Aragon Pharmaceuticals, Inc. | Process for the preparation of a diarylthiohydantoin compound |
-
2015
- 2015-12-17 WO PCT/US2015/066356 patent/WO2016100652A2/en active Application Filing
- 2015-12-17 RS RS20201378A patent/RS61060B9/sr unknown
- 2015-12-17 SG SG10201912811QA patent/SG10201912811QA/en unknown
- 2015-12-17 RS RS20220542A patent/RS63455B1/sr unknown
- 2015-12-17 HU HUE18169756A patent/HUE052475T2/hu unknown
- 2015-12-17 EA EA201892485A patent/EA201892485A1/ru unknown
- 2015-12-17 CN CN201580069602.5A patent/CN107108507A/zh active Pending
- 2015-12-17 SG SG10201912802XA patent/SG10201912802XA/en unknown
- 2015-12-17 SG SG10201912805SA patent/SG10201912805SA/en unknown
- 2015-12-17 DK DK18169895.2T patent/DK3372585T3/da active
- 2015-12-17 EP EP18169895.2A patent/EP3372585B1/en active Active
- 2015-12-17 NZ NZ732766A patent/NZ732766A/en unknown
- 2015-12-17 PL PL18169756T patent/PL3372584T3/pl unknown
- 2015-12-17 KR KR1020177019551A patent/KR102586059B1/ko active IP Right Grant
- 2015-12-17 EA EA201892487A patent/EA201892487A1/ru unknown
- 2015-12-17 HR HRP20220750TT patent/HRP20220750T1/hr unknown
- 2015-12-17 SI SI201530599T patent/SI3233803T1/sl unknown
- 2015-12-17 ME MEP-2019-86A patent/ME03420B/me unknown
- 2015-12-17 LT LTEP18169756.6T patent/LT3372584T/lt unknown
- 2015-12-17 PL PL18169895.2T patent/PL3372585T3/pl unknown
- 2015-12-17 MA MA41200A patent/MA41200B1/fr unknown
- 2015-12-17 US US14/973,089 patent/US9688655B2/en active Active
- 2015-12-17 EP EP18170050.1A patent/EP3372586A1/en not_active Withdrawn
- 2015-12-17 SI SI201531433T patent/SI3372584T1/sl unknown
- 2015-12-17 MX MX2017008179A patent/MX2017008179A/es active IP Right Grant
- 2015-12-17 JP JP2017532725A patent/JP6681902B2/ja active Active
- 2015-12-17 EA EA201791390A patent/EA201791390A1/ru unknown
- 2015-12-17 EP EP15823875.8A patent/EP3233803B1/en active Active
- 2015-12-17 ES ES18169895T patent/ES2919951T3/es active Active
- 2015-12-17 ES ES15823875T patent/ES2718539T3/es active Active
- 2015-12-17 DK DK15823875.8T patent/DK3233803T3/en active
- 2015-12-17 HU HUE15823875A patent/HUE042409T2/hu unknown
- 2015-12-17 CA CA2970937A patent/CA2970937A1/en active Pending
- 2015-12-17 ES ES18169756T patent/ES2827549T3/es active Active
- 2015-12-17 UA UAA201707588A patent/UA123201C2/uk unknown
- 2015-12-17 DK DK18169756.6T patent/DK3372584T5/da active
- 2015-12-17 PT PT181697566T patent/PT3372584T/pt unknown
- 2015-12-17 SI SI201531848T patent/SI3372585T1/sl unknown
- 2015-12-17 PT PT181698952T patent/PT3372585T/pt unknown
- 2015-12-17 LT LTEP18169895.2T patent/LT3372585T/lt unknown
- 2015-12-17 PT PT15823875T patent/PT3233803T/pt unknown
- 2015-12-17 MD MDE20170208T patent/MD3233803T2/ro unknown
- 2015-12-17 SG SG11201704969QA patent/SG11201704969QA/en unknown
- 2015-12-17 TR TR2019/04739T patent/TR201904739T4/tr unknown
- 2015-12-17 LT LTEP15823875.8T patent/LT3233803T/lt unknown
- 2015-12-17 EP EP18169756.6A patent/EP3372584B9/en active Active
- 2015-12-17 BR BR112017013113-7A patent/BR112017013113B1/pt active IP Right Grant
- 2015-12-17 RS RS20190350A patent/RS58454B1/sr unknown
- 2015-12-17 PL PL15823875T patent/PL3233803T3/pl unknown
- 2015-12-17 AU AU2015364537A patent/AU2015364537B2/en active Active
- 2015-12-17 EA EA201892486A patent/EA201892486A1/ru unknown
- 2015-12-18 TW TW108131623A patent/TWI689494B/zh active
- 2015-12-18 TW TW104142692A patent/TWI683810B/zh active
- 2015-12-18 TW TW108131622A patent/TWI703132B/zh active
- 2015-12-18 TW TW108146841A patent/TWI753336B/zh active
- 2015-12-21 AR ARP150104237A patent/AR103228A1/es unknown
-
2017
- 2017-06-12 IL IL252843A patent/IL252843A0/en unknown
- 2017-06-19 PH PH12017501152A patent/PH12017501152A1/en unknown
- 2017-07-18 ZA ZA2017/04877A patent/ZA201704877B/en unknown
-
2019
- 2019-03-19 HR HRP20190540TT patent/HRP20190540T1/hr unknown
- 2019-04-10 CY CY20191100400T patent/CY1121684T1/el unknown
-
2020
- 2020-03-24 JP JP2020052658A patent/JP6903785B2/ja active Active
- 2020-11-02 CY CY20201101031T patent/CY1123611T1/el unknown
- 2020-11-20 HR HRP20201847TT patent/HRP20201847T2/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501152A1 (en) | Process for the preparation of a diarylthiohydantoin compound | |
| PH12017501151A1 (en) | Processes for the preparation of a diarylthiohydantoin compound | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| EP3423488A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP3800248A3 (en) | Crispr-cas-related methods, compositions and components for cancer immunotherapy | |
| WO2018136617A3 (en) | Bacteria for treating cancer | |
| EP3442946A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP3606531A4 (en) | CANCER TREATMENT METHODS | |
| MX2020007742A (es) | Procesos para preparar fluorocetolidos. | |
| EP3487999A4 (en) | METHODS OF TREATING CANCER | |
| MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
| EP3723765A4 (en) | CANCER TREATMENT METHODS | |
| MX2017002609A (es) | Procedimiento mejorado para la preparacion de lacosamida y su intermediario novedoso. | |
| EP3669279A4 (en) | METHOD OF TREATMENT OF CANCER BY INHIBITION OF SETD2 | |
| MX2019003311A (es) | Metodos para tratamiento de cancer de ovario. | |
| EP3592357A4 (en) | METHOD OF TREATMENT OF CANCER | |
| EP3442555A4 (en) | METHODS OF TREATING BREAST CANCER | |
| EP3407906A4 (en) | METHOD FOR THE TARGETED INTRAPROSTATIC ADMINISTRATION OF PRX302 FOR THE TREATMENT OF PROSTATE CANCER | |
| EP3389670A4 (en) | METHODS OF TREATING BREAST CANCER | |
| PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro | |
| AU2016902922A0 (en) | Methods of Treating Cancer (I) | |
| AU2016902923A0 (en) | Methods of Treating Cancer (II) | |
| EP3125878A4 (en) | Methods of treating breast cancer | |
| IN2014CH02021A (uk) |